• Search
  • Login
  • Register
Menu
  • Last issue
  • Home
  • News
  • CongressUpdate
  • Specials
  • Guidelines
  • Links
All
  • All
  • BJMO articles
  • Blog articles
  • Specials
Forgot Password? Not a member yet? Register here
News > ASCO GU 2022

Category

All
  • Pharma News
  • Health of Tomorrow
  • Opinion
  • Art Corner
  • Fundraising
  • Prevention
  • Science
  • Clinical Practice
  • Corona
  • Cancer trials
  • Healthy Living
  • Medical Research
  • Art on View
  • Viewpoints
  • Therapy
  • Health Innovation
  • Podcasts
  • Editor's pick
  • Special
  • BSMO Meeting 2021
  • Covid-19
  • EADO 2021
  • Society Announcement

ASCO GU 2022

Olaparib plus abiraterone as first-line therapy for patients with metastatic castration-resist...

Read more
subscribe Latest issue All issues Newsletters
Index latest issue
  • INTRODUCTION
  • Emerging therapies in gynaecological cancers (part 1) : Locally advanced and metastatic cervical cancer
  • Clinical application of circulating tumour DNA (ctDNA) in breast cancer management
  • Support for bowel problems after rectal cancer during a nursing consultation
  • “Right to be forgotten” (RTBF) for cancer survivors: The Belgium situation
  • Highlights of the Gastrointestinal Cancers Symposium 2025
  • SABCS 2024: Highlights of new data on systemic therapy for breast cancer
  • New oncology reimbursements in Belgium
ASCO GU 2022

Promising antitumour activity with neoadjuvant enfortumab vedotin in cisplatin-ineligible musc...

Read more
Top

Join our newsletter

  • This field is for validation purposes and should be left unchanged.
  • About BJMO
  • Ads & sponsoring
  • Vacancies
  • Disclaimer
  • Privacy
  • Contact

BJMO is published by Ariez International BV, Westzijde 22, 1506 EE Zaandam, The Netherlands

© BJMO 2025

Manage Cookie Consent

To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Statistics

Marketing

Features
Always active

Always active
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}